Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
- Earlier this month, Neurocrine Biosciences reported Phase 4 KINECT-PRO results showing once-daily INGREZZA improved patient-reported quality of life, functioning, and clinician-rated tardive dyskinesia severity over 24 weeks, with no new safety issues.
- The study uniquely used the company’s own Tardive Dyskinesia Impact Scale alongside other validated patient-reported tools, giving a more patient-centric view of INGREZZA’s real-world benefit across differing psychiatric diagnoses and movement severities.
- We’ll now examine how these patient-centered KINECT-PRO findings may influence Neurocrine’s investment narrative built around INGREZZA’s neurology leadership.
Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
Neurocrine Biosciences Investment Narrative Recap
To own Neurocrine, you need to believe INGREZZA can remain a high-value neurology franchise while the company reduces its reliance on a single product and manages pricing pressure. The new KINECT-PRO Phase 4 data deepen the clinical story around quality-of-life benefits but do not materially change the near term catalyst, which is continued INGREZZA volume growth under tighter Medicare and payer scrutiny, or the key risk of margin pressure from contracting and potential future pricing reforms.
Among recent updates, the launch of the Phase 1 study for NBIP-1968, a triple agonist for obesity, stands out as most relevant. It highlights Neurocrine’s push to broaden its portfolio beyond movement disorders, which could matter over time if INGREZZA or CRENESSITY face tougher pricing or competitive headwinds, but it is still very early and does not yet rival INGREZZA-focused catalysts that drive the nearer term story.
Yet investors should also weigh how intensified payer scrutiny and rebate pressure could reshape INGREZZA’s contribution to profits and cash flow...
Read the full narrative on Neurocrine Biosciences (it's free!)
Neurocrine Biosciences' narrative projects $5.2 billion revenue and $1.4 billion earnings by 2029. This requires 15.6% yearly revenue growth and roughly a $694.5 million earnings increase from $705.5 million today.
Uncover how Neurocrine Biosciences' forecasts yield a $213.13 fair value, a 40% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming revenue could reach about US$6.4 billion with earnings near US$2.7 billion by 2029, while also counting on INGREZZA expansion and robust pricing. The new KINECT-PRO results may support those views or prompt revisions, and you should recognize that reasonable investors can see very different futures for Neurocrine.
Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $211.57!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.
Want Some Alternatives?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com